Hudson Bay Capital Management
IONS icon

Hudson Bay Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Hudson Bay Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,000
Closed -$1.48M – 1285
2022
Q2 		$1.48M Hold
40,000
– – 0.01% 864
2022
Q1 		$1.48M Buy
+40,000
New +$1.31M 0.02% 767

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hudson Bay Capital Management's IONS Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Ionis Pharmaceuticals (IONS) stake by 51% in Q2 2026, selling an estimated $11.3M and leaving 145,000 shares worth $11.5M. The position accounts for 0.03% of the portfolio, ranked #332.

Hudson Bay Capital Management first reported a position in IONS in Q1 2018 and has held it in 30 quarters since. The position peaked at $37.6M in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Hudson Bay Capital Management held 145,000 shares of Ionis Pharmaceuticals worth $11.5M as of Q2 2026.
  • Hudson Bay Capital Management sold 150,100 Ionis Pharmaceuticals shares in Q2 2026, an estimated $11.3M.
  • Ionis Pharmaceuticals made up 0.03% of Hudson Bay Capital Management's portfolio in Q2 2026, its #332 holding.
  • Hudson Bay Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
  • Hudson Bay Capital Management's Ionis Pharmaceuticals position peaked at $37.6M in Q4 2025.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.